NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Depending on the exchange, the stock ticker may vary. For instance, on exchange Stablecoin Development stocks are traded under the ticker B9P1.STU.
What were Stablecoin Development earnings last quarter?▼
B9P1.STU earnings for the last quarter are -0.99 EUR per share, whereas the estimation was -0.91 EUR resulting in a -9.52% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Stablecoin Development have?▼
As of April 12, 2026, the company has 13 employees.
In which sector is Stablecoin Development located?▼
Stablecoin Development operates in the Health & Wellness sector.
When did Stablecoin Development complete a stock split?▼
Stablecoin Development has not had any recent stock splits.
Where is Stablecoin Development headquartered?▼
Stablecoin Development is headquartered in Emeryville, United States.